Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
graham.mcclorey@paediatrics.ox.ac.uk

Graham McClorey

Senior Post Doctoral Researcher/Team Leader

The current focus is understanding and improving upon cell penetrating peptide design to enhance the therapeutic potential of antisense oligonucleotides, in particular for neuromuscular disorders. I am also studying the potential benefit of stereopure oligonucleotides in a severe model of DMD (DKO) through collaboration with Wave LifeSciences.

Recent publications

Cell-Penetrating Peptides to Enhance Delivery of Oligonucleotide-Based Therapeutics.

McClorey G. and Banerjee S., (2018), Biomedicines, 6

Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy.

Blain AM. et al, (2018), PLoS One, 13

PROFILE OF CIRCADIANLY REGULATED METABOLIC GENES IN DYSTROPHIC HEART

Betts CA. et al, (2018), HEART, 104, A4 - A4

Splice-Switching Therapy for Spinal Muscular Atrophy.

Meijboom KE. et al, (2017), Genes (Basel), 8

Preclinical studies of WVE-210201, an investigational stereopure antisense oligonucleotide in development for the treatment of patients with duchenne muscular dystrophy (DMD)

Panzara M. et al, (2017), JOURNAL OF THE NEUROLOGICAL SCIENCES, 381, 277 - 278